Atika Capital Management Invests $1.41M in Ionis Pharmaceuticals

Got story updates? Submit your updates here. ›

Atika Capital Management LLC acquired a new stake of 21,500 shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the third quarter, valued at approximately $1.41 million. The investment was disclosed in Atika's recent 13F filing with the Securities and Exchange Commission.

Why it matters

Ionis Pharmaceuticals is a prominent biotech company focused on developing RNA-targeted therapies for a range of diseases. This new investment by Atika Capital Management, a hedge fund, suggests institutional investor confidence in Ionis' pipeline and future growth potential.

The details

According to the 13F filing, Atika Capital Management acquired the 21,500 shares of Ionis Pharmaceuticals during the third quarter of the year. This new stake represents Atika's first investment in the biotech firm. Other institutional investors have also recently added to or reduced their positions in Ionis, with some firms like Golden State Wealth Management and Meeder Asset Management increasing their holdings.

• Atika Capital Management acquired the 21,500 Ionis shares in the third quarter of 2026.